Pharming Group N.V. Reports Third Quarter 2026 Financial Results
Pharming Group N.V. has released its preliminary, unaudited financial report for the third quarter ended September 30, 2026.
Stocks · News reference
Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
U.S. stocks fell, led by a 2% Nasdaq drop; Lockheed Martin beat estimates and raised guidance. Oil rose, while global markets and metals declined.
Pharming Group Announces Third Quarter 2026 Revenues Above Market Expectations
Pharming Group N.V. reported its financial results for the third quarter of 2026, noting that revenues exceeded market expectations.